211 related articles for article (PubMed ID: 18580862)
61. Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-γ in macrophages.
Matsumura T; Kinoshita H; Ishii N; Fukuda K; Motoshima H; Senokuchi T; Taketa K; Kawasaki S; Nishimaki-Mogami T; Kawada T; Nishikawa T; Araki E
Arterioscler Thromb Vasc Biol; 2011 Jun; 31(6):1268-75. PubMed ID: 21474824
[TBL] [Abstract][Full Text] [Related]
62. ONTARGET to provide new treatment strategies for high-risk cardiovascular patients. Understanding the role of PPARgamma in blood pressure control.
Cardiovasc J Afr; 2007; 18(3):186-7. PubMed ID: 17612754
[No Abstract] [Full Text] [Related]
63. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
[TBL] [Abstract][Full Text] [Related]
64. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
[TBL] [Abstract][Full Text] [Related]
65. Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome.
Rinaldi B; Di Filippo C; Capuano A; Donniacuo M; Sodano L; Ferraraccio F; Rossi F; D'Amico M
Diabetes Obes Metab; 2012 Apr; 14(4):320-8. PubMed ID: 22050607
[TBL] [Abstract][Full Text] [Related]
66. Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Storka A; Vojtassakova E; Mueller M; Kapiotis S; Haider DG; Jungbauer A; Wolzt M
Eur J Clin Invest; 2008 Nov; 38(11):820-6. PubMed ID: 19021699
[TBL] [Abstract][Full Text] [Related]
67. Structural basis for telmisartan-mediated partial activation of PPAR gamma.
Amano Y; Yamaguchi T; Ohno K; Niimi T; Orita M; Sakashita H; Takeuchi M
Hypertens Res; 2012 Jul; 35(7):715-9. PubMed ID: 22357520
[TBL] [Abstract][Full Text] [Related]
68. Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.
Tuck ML
Curr Hypertens Rep; 2005 Aug; 7(4):240-3. PubMed ID: 16061040
[TBL] [Abstract][Full Text] [Related]
69. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
Schupp M; Clemenz M; Gineste R; Witt H; Janke J; Helleboid S; Hennuyer N; Ruiz P; Unger T; Staels B; Kintscher U
Diabetes; 2005 Dec; 54(12):3442-52. PubMed ID: 16306360
[TBL] [Abstract][Full Text] [Related]
70. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
[TBL] [Abstract][Full Text] [Related]
71. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation.
Yoshida T; Yamagishi S; Matsui T; Nakamura K; Ueno T; Takeuchi M; Sata M
J Int Med Res; 2008; 36(2):237-43. PubMed ID: 18380932
[TBL] [Abstract][Full Text] [Related]
72. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
Yamagishi S; Nakamura K; Matsui T
Curr Mol Med; 2007 Aug; 7(5):463-9. PubMed ID: 17691961
[TBL] [Abstract][Full Text] [Related]
73. Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.
Aubert G; Burnier M; Dulloo A; Perregaux C; Mazzolai L; Pralong F; Zanchi A
Metabolism; 2010 Jan; 59(1):25-32. PubMed ID: 19793594
[TBL] [Abstract][Full Text] [Related]
74. Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.
Francischetti EA; Celoria BM; Francischetti A; Genelhu VA
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):289-303. PubMed ID: 18327991
[TBL] [Abstract][Full Text] [Related]
75. Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization.
Nagai N; Oike Y; Izumi-Nagai K; Urano T; Kubota Y; Noda K; Ozawa Y; Inoue M; Tsubota K; Suda T; Ishida S
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2252-9. PubMed ID: 16888236
[TBL] [Abstract][Full Text] [Related]
76. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties.
Deppe S; Böger RH; Weiss J; Benndorf RA
Expert Opin Drug Metab Toxicol; 2010 Jul; 6(7):863-71. PubMed ID: 20509777
[TBL] [Abstract][Full Text] [Related]
77. Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma.
Yao Y; Zou R; Liu X; Jiang J; Huang Q; He Y; Li M; Wang S; Zhou J; Ma D; Xu G
J Huazhong Univ Sci Technolog Med Sci; 2008 Oct; 28(5):543-8. PubMed ID: 18846335
[TBL] [Abstract][Full Text] [Related]
78. Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPARγ activation.
Wang J; Pang T; Hafko R; Benicky J; Sanchez-Lemus E; Saavedra JM
Neuropharmacology; 2014 Apr; 79():249-61. PubMed ID: 24316465
[TBL] [Abstract][Full Text] [Related]
79. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Pershadsingh HA
Int J Biochem Cell Biol; 2006; 38(5-6):766-81. PubMed ID: 16298156
[TBL] [Abstract][Full Text] [Related]
80. Are the pleiotropic effects of telmisartan clinically relevant?
Rizos CV; Elisaf MS; Liberopoulos EN
Curr Pharm Des; 2009; 15(24):2815-32. PubMed ID: 19689352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
